MV Capital Management’s Intellia Therapeutics NTLA Stock Holding History

MV Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$914	Hold	54	–	–	﹤0.01%	928
2026 Q1	$693	Hold	54	–	–	﹤0.01%	922
2025 Q4	$486	Hold	54	–	–	﹤0.01%	921
2025 Q3	$933	Hold	54	–	–	﹤0.01%	798
2025 Q2	$507	Buy	54 +3	+6%	+$25	﹤0.01%	844
2025 Q1	$363	Sell	51 -37	-42%	-$374	﹤0.01%	852
2024 Q4	$1.03K	Buy	88 +65	+283%	+$1.01K	﹤0.01%	747
2024 Q3	$473	Buy	23 +18	+360%	+$415	﹤0.01%	811
2024 Q2	$112	Sell	5 -1	-17%	-$24	﹤0.01%	879
2024 Q1	$166	Buy	+6	New	+$167	﹤0.01%	739

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

MV Capital Management's NTLA Position: Q2 2026 in Review

MV Capital Management held its Intellia Therapeutics (NTLA) position steady in Q2 2026 at 54 shares worth $914. The position accounts for ﹤0.01% of the portfolio, ranked #928.

MV Capital Management first reported a position in NTLA in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.03K in Q4 2024. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

MV Capital Management held 54 shares of Intellia Therapeutics worth $914 as of Q2 2026.
MV Capital Management left its Intellia Therapeutics share count unchanged in Q2 2026.
Intellia Therapeutics made up ﹤0.01% of MV Capital Management's portfolio in Q2 2026, its #928 holding.
MV Capital Management first reported a position in Intellia Therapeutics in Q1 2024 and has held it in 10 quarters since.
MV Capital Management's Intellia Therapeutics position peaked at $1.03K in Q4 2024.
328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on MV Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.